ArticleSchizophrenia research2012
Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia.
Article in Schizophrenia research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.The American journal of psychiatry · 2026Review
- Article
- Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: A pilot study.Neurobiology of disease · 2023Article
- Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: a pilot study.bioRxiv : the preprint server for biology · 2023Article
- Design and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CBMicrobial cell factories · 2022Article
- Cannabinoids, reward processing, and psychosis.Psychopharmacology · 2022Review
- Endocannabinoid system in psychotic and mood disorders, a review of human studies.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use.Schizophrenia bulletin · 2020Article
- Effects of combined 5-HTPsychopharmacology · 2020Article
- Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review.Brain sciences · 2020Review
- Endocannabinoid System Components as Potential Biomarkers in Psychiatry.Frontiers in psychiatry · 2020Review
- In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis.JAMA psychiatry · 2019Article
- Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.CNS drugs · 2018Review
- Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia.Molecular neurobiology · 2017Review
- Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research.Frontiers in pharmacology · 2017Review
- Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders.Current neuropharmacology · 2017Review
- Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.Biological psychiatry · 2016Article
- The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.Biological psychiatry · 2016Review
- Social Stress and Psychosis Risk: Common Neurochemical Substrates?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Review
- Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.Current medicinal chemistry · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
This study sought to determine whether cannabinoid-1 (CB(1)) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n=47) compared to controls (n=43). The CB(1) receptor inverse agonist radioligand [(3)H]MePPEP was used to measure specific binding to CB(1) receptors. The specific binding of [(3)H]MePPEP to CB(1) receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [(18)F]FMPEP-d(2) (80% statistical power, p<0.05).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.